Clinicians could predict long-term risk of breast cancer returning with a new online tool
A new, simple web-based calculator that could better predict the long term risk of breast cancer returning in other areas of the body has today been published online by researchers at The Royal Marsden NHS Foundation Trust and Queen Mary University of London.
The prognostic tool – CTS5 (Clinical Treatment Score post-5-years) – published recently in the Journal of Clinical Oncology, could be used to decide which patients are at high enough risk of their cancer returning after receiving the standard five years of endocrine (hormone) therapy, and so could benefit from continuation of treatment. It could also predict which patients are at low risk of recurrence, and so can avoid any further therapy along with the potential adverse side effects.
Over the last three decades, there has been a major increase in the rate of invasive breast cancer in Western countries. Approximately 85 per cent of patients are now diagnosed as oestrogen receptor (ER) positive, which means that the cancer grows in response to the hormone oestrogen. Almost all of these patients are prescribed five years of hormone therapy after having standard treatment (surgery, chemotherapy, and/or radiation therapy), to lower the risk of the cancer returning.
However, hormone therapy can have significant side effects for some patients, including weakness of bone tissue, and exacerbation of menopausal symptoms. Oncologists along with patients have to decide after five years of hormone treatment whether extending this type of therapy is worthwhile and appropriate.
Researchers developed CTS5 after reviewing data from two previously published studies. Together these provided information on 11,446 postmenopausal women with ER positive breast cancer who had received five years of hormone therapy (tamoxifen, anastrozole, or letrozole).
Using the data set from one previously published study, they measured how many women developed metastasis five to 10 years after they finished endocrine therapy. This was then combined with information about the tumour, which had been measured at the point of diagnosis, to produce a risk equation – CTS5.
To investigate the validity of the tool, researchers then tested CTS5 against data from the second study. CTS5 was shown to be able to accurately separate women into groups of low, intermediate, or high risk of developing a late distant recurrence breast cancer after five years of hormone therapy. The test identified 42 per cent of women as who were sufficiently low risk so that extending hormone therapy would have been of very little value.
Co-lead researcher Professor Mitch Dowsett, Head of The Royal Marsden Ralph Lauren Centre for Breast Cancer Research, said: “What we have developed could improve clinical practice, benefiting breast cancer patients by avoiding potentially unnecessary extended treatment. Clinicians require expertise and the best tools to help them make crucial decision on treatment for patients, decisions that can make a difference to patient’s quality of life.”
Pat Cook, 66, was diagnosed with breast cancer in 2015 and treated at The Royal Marsden. She says: “I had a complete conveyor belt of treatments; two breast operations, chemotherapy and radiotherapy. Thankfully my treatment was successful and so I since have been on endocrine therapy.
“I think this research is really important for patients. The side effects of endocrine therapy aren’t very pleasant – for about 18 months I felt I was about 40 years older with hip pains and tiredness. It’s a bit disappointing that after everything you can’t just bounce back. So it’s definitely good news for those patients who might not have to extend their therapy, and so can avoid the potential side effects.
“Psychologically as well it makes a difference. When you’ve finished treatment you’re over the moon that you’re clear. But in the background there’s always that little worry of ‘will it return?. Whether you end up having to extend your therapy or not, it’s reassuring to know that your doctors are making decisions based on up-to-date research. It gives you confidence in the treatment you are given.”
Professor Dowsett, who is also Professor of Biochemical Endocrinology at The Institute of Cancer Research, London, added: “This tool uses information that is already gathered in all patients, so could be easily used across the UK and globally at other centres.”
The authors note that the data used was from previously published studies that began over 20 years ago on patients with hormone receptor positive tumours (make up about 85% of breast cancer). The only major change to the management of this specific patient population since then has been the introduction of trastuzumab for some patients, and so clinicians who are treating this specific group should be cautious of using CTS5.
Professor David Cunningham, Director of the NIHR Biomedical Research Centre at The Royal Marsden NHS Foundation Trust and the Institute of Cancer Research, London, said: “This is an incredibly important piece of research in the delivery of precision medicine, which has been supported by the NIHR. It should allow clinicians to select the patients who really need hormone treatment after surgical removal of the primary breast cancer, using a 21st century tool.”
This study was supported by NIHR Biomedical Research Centre at The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, London, Cancer Research UK and the Susan G. Komen Foundation.